Chronic inflammation's transformation to cancer : a nanotherapeutic paradigm

Tools

Sohrab, Sayed Sartaj and Raj, Riya and Nagar, Amka and Hawthorne, Susan and Paiva-Santos, Ana Cláudia and Kamal, Mohammad Amjad and El-Daly, Mai M. and Azhar, Esam I. and Sharma, Ankur (2023) Chronic inflammation's transformation to cancer : a nanotherapeutic paradigm. Molecules, 28 (11). 4413. ISSN 1420-3049 (https://doi.org/10.3390/molecules28114413)

[thumbnail of Sohrab-etal-Molecules-2023-Chronic-inflammations-transformation-to-cancer]
Preview
 Text. Filename: Sohrab_etal_Molecules_2023_Chronic_inflammations_transformation_to_cancer.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (1MB)| Preview

Abstract

The body’s normal immune response against any invading pathogen that causes infection in the body results in inflammation. The sudden transformation in inflammation leads to the rise of inflammatory diseases such as chronic inflammatory bowel disease, autoimmune disorders, and colorectal cancer (different types of cancer develop at the site of chronic infection and inflammation). Inflammation results in two ways: short-term inflammation i.e., non-specific, involves the action of various immune cells; the other results in long-term reactions lasting for months or years. It is specific and causes angiogenesis, fibrosis, tissue destruction, and cancer progression at the site of inflammation. Cancer progression relies on the interaction between the host microenvironment and tumor cells along with the inflammatory responses, fibroblast, and vascular cells. The two pathways that have been identified connecting inflammation and cancer are the extrinsic and intrinsic pathways. Both have their own specific role in linking inflammation to cancer, involving various transcription factors such as Nuclear factor kappa B, Activator of transcription, Single transducer, and Hypoxia-inducible factor, which in turn regulates the inflammatory responses via Soluble mediators cytokines (such as Interleukin-6, Hematopoietin-1/Erythropoietin, and tumor necrosis factor), chemokines (such as Cyclooxygenase-2, C-X-C Motif chemokines ligand-8, and IL-8), inflammatory cells, cellular components (such as suppressor cells derived from myeloid, tumor-associated macrophage, and acidophils), and promotes tumorigenesis. The treatment of these chronic inflammatory diseases is challenging and needs early detection and diagnosis. Nanotechnology is a booming field nowadays for its rapid action and easy penetration inside the infected destined cells. Nanoparticles are widely classified into different categories based on their different factors and properties such as size, shape, cytotoxicity, and others. Nanoparticles emerged as excellent with highly progressive medical inventions to cure diseases such as cancer, inflammatory diseases, and others. Nanoparticles have shown higher binding capacity with the biomolecules in inflammation reduction and lowers the oxidative stress inside tissue/cells. In this review, we have overall discussed inflammatory pathways that link inflammation to cancer, major inflammatory diseases, and the potent action of nanoparticles in chronic inflammation-related diseases.

ORCID iDs

Sohrab, Sayed Sartaj, Raj, Riya, Nagar, Amka, Hawthorne, Susan, Paiva-Santos, Ana Cláudia, Kamal, Mohammad Amjad, El-Daly, Mai M., Azhar, Esam I. and Sharma, Ankur ORCID logoORCID: https://orcid.org/0000-0003-3058-760X;
CORE (COnnecting REpositories)